Gene editing takes a major step toward ending daily cholesterol pills
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If successful, it could be the first approved genetic-silencing method on the market, replacing the need for long-term medication and slashing the risk of cardiovascular disease.
Category: Heart Disease, Illnesses and conditions, Body and Mind
Tags: Biotechnology, CRISPR, clinical trials, gene therapy, Genetic engineering, Genome
